Filtered By:
Source: American Heart Journal
Condition: Burns
Drug: Fortamet
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
